Document Detail


Multitargeted therapy of cancer by silymarin.
MedLine Citation:
PMID:  18472213     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Silymarin, a flavonolignan from milk thistle (Silybum marianum) plant, is used for the protection against various liver conditions in both clinical settings and experimental models. In this review, we summarize the recent investigations and mechanistic studies regarding possible molecular targets of silymarin for cancer prevention. Number of studies has established the cancer chemopreventive role of silymarin in both in vivo and in vitro models. Silymarin modulates imbalance between cell survival and apoptosis through interference with the expressions of cell cycle regulators and proteins involved in apoptosis. In addition, silymarin also showed anti-inflammatory as well as anti-metastatic activity. Further, the protective effects of silymarin and its major active constituent, silibinin, studied in various tissues, suggest a clinical application in cancer patients as an adjunct to established therapies, to prevent or reduce chemotherapy as well as radiotherapy-induced toxicity. This review focuses on the chemistry and analogues of silymarin, multiple possible molecular mechanisms, in vitro as well as in vivo anti-cancer activities, and studies on human clinical trials.
Authors:
Kumaraguruparan Ramasamy; Rajesh Agarwal
Related Documents :
23510063 - Causes of death due to hematological and non-hematological cancers in 57 us patients wi...
24523813 - The significance of caspase-cleaved cytokeratin 18 in pleural effusion.
19519883 - Synthetic lethal rnai screening identifies sensitizing targets for gemcitabine therapy ...
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review     Date:  2008-05-09
Journal Detail:
Title:  Cancer letters     Volume:  269     ISSN:  1872-7980     ISO Abbreviation:  Cancer Lett.     Publication Date:  2008 Oct 
Date Detail:
Created Date:  2008-09-15     Completed Date:  2008-10-14     Revised Date:  2013-06-05    
Medline Journal Info:
Nlm Unique ID:  7600053     Medline TA:  Cancer Lett     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  352-62     Citation Subset:  IM    
Affiliation:
Department of Pharmaceutical Sciences, School of Pharmacy, University of Colorado Denver, 4200 East Ninth Street, Box C238, Denver, CO 80262, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiogenesis Inhibitors / pharmacology
Animals
Anti-Inflammatory Agents / pharmacology
Anticarcinogenic Agents / pharmacology*
Antioxidants / pharmacology
Apoptosis / drug effects
Cell Cycle / drug effects
Clinical Trials as Topic
Humans
Neoplasm Metastasis / prevention & control
Neoplasms / drug therapy*
Silymarin / chemistry,  metabolism,  pharmacology*
Grant Support
ID/Acronym/Agency:
R01 CA102514/CA/NCI NIH HHS; R01 CA102514-05/CA/NCI NIH HHS; R01 CA104286/CA/NCI NIH HHS; R01 CA112304/CA/NCI NIH HHS; R01 CA112304-04/CA/NCI NIH HHS; R01 CA113876/CA/NCI NIH HHS; R01 CA113876-04/CA/NCI NIH HHS; R01 CA116636/CA/NCI NIH HHS; R01 CA116636-03/CA/NCI NIH HHS; R01 CA64514/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Anti-Inflammatory Agents; 0/Anticarcinogenic Agents; 0/Antioxidants; 0/Silymarin
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Transcriptional auto-regulation of the dopamine receptor regulating factor (DRRF) gene.
Next Document:  Olfactory lateralization: odor intensity but not the hedonic estimation is lateralized.